1. Home
  2. INO vs RCEL Comparison

INO vs RCEL Comparison

Compare INO & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

HOLD

Current Price

$1.55

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.86

Market Cap

132.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INO
RCEL
Founded
1979
N/A
Country
United States
United States
Employees
N/A
226
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
132.0M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
INO
RCEL
Price
$1.55
$3.86
Analyst Decision
Buy
Buy
Analyst Count
5
5
Target Price
$9.00
$7.88
AVG Volume (30 Days)
647.3K
179.9K
Earning Date
03-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
54.18
N/A
EPS
N/A
N/A
Revenue
$42,220,086.00
N/A
Revenue This Year
$24,407.60
$17.17
Revenue Next Year
$331.40
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
19.37
N/A
52 Week Low
$1.30
$3.22
52 Week High
$2.86
$10.28

Technical Indicators

Market Signals
Indicator
INO
RCEL
Relative Strength Index (RSI) 38.30 37.95
Support Level $1.48 $3.33
Resistance Level $1.60 $4.09
Average True Range (ATR) 0.07 0.28
MACD -0.02 -0.11
Stochastic Oscillator 6.25 12.67

Price Performance

Historical Comparison
INO
RCEL

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: